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Abstract
Background: Of the estimated 10–11 year life expectancy gap between Indigenous (Aboriginal and Torres Strait
Islander people) and non-Indigenous Australians, approximately one quarter is attributable to cardiovascular disease
(CVD). Risk prediction of CVD is imperfect, but particularly limited for Indigenous Australians. The BIRCH (Better
Indigenous Risk stratification for Cardiac Health) project aims to identify and assess existing and novel markers of
early disease and risk in Indigenous Australians to optimise health outcomes in this disadvantaged population. It
further aims to determine whether these markers are relevant in non-Indigenous Australians.
Methods/design: BIRCH is a cross-sectional and prospective cohort study of Indigenous and non-Indigenous
Australian adults (≥ 18 years) living in remote, regional and urban locations. Participants will be assessed for CVD
risk factors, left ventricular mass and strain via echocardiography, sleep disordered breathing and quality via
home-based polysomnography or actigraphy respectively, and plasma lipidomic profiles via mass spectrometry.
Outcome data will comprise CVD events and death over a period of five years.
Discussion: Results of BIRCH may increase understanding regarding the factors underlying the increased burden of
CVD in Indigenous Australians in this setting. Further, it may identify novel markers of early disease and risk to
inform the development of more accurate prediction equations. Better identification of at-risk individuals will
promote more effective primary and secondary preventive initiatives to reduce Indigenous Australian health
disadvantage.
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Background
Aboriginal Australian and/or Torres Strait Islander peo-
ples (Indigenous Australians) have well-documented
health disadvantage in comparison with non-Indigenous
Australians [1]. Addressing health disparities in an
Australian Indigenous setting ultimately rests on the de-
velopment and implementation of primordial and pri-
mary prevention strategies to address population and
individual risk factors that facilitate disease development.
In the interim, secondary prevention strategies are re-
quired to identify and manage people with established
disease to prevent progression and complications.
There is an estimated 10–11 year gap between Indi-
genous and non-Indigenous Australian life expectancy at
birth and, of this, one quarter is attributable to cardiovascu-
lar disease (CVD) [2]. Importantly, the pattern and natural
history of CVD that presents in Indigenous communities is
quite different to that seen in other Australian communities
[3, 4]. For example, a recent study in central Australia [5]
reported that 5% of a sample of Aboriginal adults had evi-
dence of heart failure, up to four times the reported preva-
lence of heart failure in the overall Australian population
[6], with an onset at an earlier age.
There is, therefore, a strong rationale to develop more
culturally and contextually appropriate strategies to ad-
dress the disparity in life expectancy between Indigenous
and non-Indigenous Australians resulting from CVD. In
particular, improvements in the primary and secondary
prevention of CVDs in Indigenous Australians has the
potential to significantly reduce this gap. This paper de-
scribes the BIRCH (Better Indigenous Risk stratification
for Cardiac Health) project that aims to assess cardio-
vascular risk and explore the potential value of novel
cardiovascular risk factors and early disease markers in
Indigenous Australians. The objective is to more accur-
ately identify Indigenous Australians at risk of overt
CVD so that preventive treatments can be commenced
sooner in those whom will receive the greatest benefit.
More specifically, BIRCH will determine whether mea-
sures of left ventricular dysfunction, sleep quality and
sleep disturbances, and detailed lipid profiles are useful in
determining the risk of development of overt CVD in
Indigenous Australians such that interventions can be
commenced to prevent or retard its development. In
addition, it will seek to determine whether there is any dif-
ference in the utility of such measures between rural and
urban Indigenous populations and whether such measures
may have relevance in non-Indigenous Australians.
Traditional cardiovascular risk stratification and
Indigenous Australians
A number of CVD risk stratification scores have been
developed to identify individuals at risk of CVD who
may benefit from the early introduction of preventive
therapies [7, 8]. One of the most extensively used predic-
tion algorithms is the Framingham Risk Score derived
from the Framingham Heart Study [9, 10]. While the
risk factors identified in this and subsequent Framingham
studies [11] (age, sex, high blood total cholesterol, low
high-density lipoprotein (HDL) cholesterol level, high sys-
tolic blood pressure, the presence of diabetes, and smok-
ing) have important utility in non-Indigenous populations,
research suggests that their predictive power in Indigen-
ous Australian populations is limited. For example, the re-
search of Wang and colleagues in remote Aboriginal
Australian communities demonstrated significant discrep-
ancies between the predicted incidence of coronary heart
disease (CHD) based on the Framingham score (4.4/1000
person-years) and observed incidence (11.0/1000 person-
years), with the greatest discrepancy occurring in younger
women in whom the observed rate of CHD was over 30
times the predicted rate [12, 13].
Such findings suggest that additional factors not in-
cluded in the Framingham functions may be important
in adding to, or interacting with, traditional CVD risk
factors to result in the increased and currently ‘unmeas-
ured’ risk of CVD in Indigenous Australians. For ex-
ample, Wang and colleagues demonstrated that waist
circumference, body mass index (BMI), hip circumfer-
ence, and high sensitivity C-reactive protein (hs-CRP)
were significantly associated with cardiovascular risk in-
dependent of other cardiovascular risk factors [14, 15].
Similarly, McDermott and McCulloch found that dia-
betes in Aboriginal Australians in remote north Queens-
land, particularly when associated with albuminuria, was
associated with a far higher risk of CHD compared with
traditional Framingham risk factors [16], while Luke
and colleagues identified hyperglycaemia (fasting glu-
cose > 4.8 mmol/L) and albuminuria (albumin:creati-
nine ratio > 5.7 mg/mmol) as clinical predictors of
primary CVD in Aboriginal Australians from central
Australia [17].
These earlier studies predominantly or exclusively in-
volved Indigenous Australians living in remote or outer
regional Australian centres. Whether their findings are
generalizable to Indigenous Australians residing in major
cities and inner regional centres, where 57% of Indigenous
Australians live [18], remains unclear. While national
Australian data would suggest the disparity between Indi-
genous and non-Indigenous CVD incidence as measured
by age standardised hospitalisation is far lower in urban as
compared with remote residing Indigenous Australians
[19], this is not reflected in single centre studies. In Brad-
shaw and colleagues’ follow-up of the Perth Aboriginal
Atherosclerosis Risk Study (PAARS) cohort, the authors
demonstrated city-based Aboriginal Australians had a
rate of first CHD events (hospital admission or CHD
death) that was far higher than city-residing non-
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Indigenous Australians [20] and comparable to Indigen-
ous Australians residing in remote Northern Territory
communities [21].
Beyond traditional risk markers for CVD
Whilst many existing and newer markers of early CVD
disease or risk may help identify Indigenous Australians
at increased risk of development of overt CVD, they
often do not independently provide new or additional
targets for primary or secondary prevention. Furthermore,
such markers continue to focus predominantly on
atherosclerosis-mediated CVD despite the increasing rec-
ognition of non-atherosclerotic causes of conditions such
as heart failure [22, 23]. We have therefore selected three
particular areas of interest that may either increase the
risk or be early markers of CVD and are potential targets
for primary and/or secondary prevention in this setting.
Sleep quality and disorders
Fatigue and poor sleep quality have been found to be re-
lated to CVD risk factors including hypertension and
CHD, attributable to increased sympathetic activity [24].
Poor sleep also predisposes to the metabolic syndrome
[25] and mood disturbance [26]. Whilst the literature
confirms poor sleep quality and duration as a risk factor
for CVD, there is little understanding of the impact of
sleep hygiene and sleep behaviours, as compared with
formal sleep disorders, in disadvantaged populations at
high CVD risk such as Indigenous Australians.
Specific sleep-related disorders such as obstructive
sleep apnoea (OSA) are associated with an increased risk
in the development and progression of CVD [27, 28].
One recent observational study demonstrated a significant
correlation between OSA and the presence of CHD, pul-
monary hypertension, congestive heart failure, cardiomy-
opathy, and arrhythmia [29]. It has also been suggested
that OSA is a risk factor for stroke and stroke-related
death [30–32]. Analysis of the Western Australian-based
Busselton Health Study, primarily in Caucasians, has con-
firmed that the presence of OSA has additional prognostic
significance for all-cause mortality and stroke incidence
beyond the risk that is explained by factors included in the
Framingham score [31]. The additional predictive ability
of OSA in Indigenous Australians is presently unknown.
Despite the evidence of an association between sleep
disorders/quality and CVD, little has been achieved in
the management of sleep disruptions for Indigenous
Australians. Indeed, one recent study demonstrated that
regional and remote Australians residents accessed diag-
nostic sleep studies at approximately 1/20th of the over-
all Australian rate [33]. Despite this lack of access, this
retrospective cohort study of 200 adults revealed that
Indigenous Australians were almost twice as likely to
have a sleep disorder diagnosed when a sleep study was
performed compared with non-Indigenous patients.
Left ventricular function and morphology
Markers of left ventricular function and morphology (in-
cluding size and mass) may represent additional markers
of either CVD risk or the earliest signs of pre-clinical
CVD. Left ventricular ejection fraction (LVEF) is one of
the most commonly used measures of left ventricular
systolic function. Whilst it has been shown to be a
strong predictor of mortality in patients with heart fail-
ure, deteriorating LVEF is often a late marker of disease.
On the contrary, patients with signs and symptoms of
heart failure or who have subsequent CVD events may
still exhibit preserved left ventricular systolic function [34,
35]. Whilst there has previously been a focus on heart fail-
ure with reduced ejection fraction (HFrEF), it is evident
that heart failure with preserved LVEF (HFpEF) is also as-
sociated with high rates of morbidity and mortality [36]. A
focus beyond LVEF in assessing left ventricular function is
therefore required to better understand whether more
subtle alternations in heart function may represent the
earliest signs of CVD, particularly at a stage when treat-
ment may reduce progression to overt CVD. Particular
targets in this regard include global longitudinal strain
(GLS) and measures of left ventricular morphology.
GLS is a novel index of myocardial deformation that
can be quantified via automated speckle tracking echo-
cardiography (STE). GLS has been validated against
tagged magnetic resonance imaging and is more accur-
ate than standard echocardiographic measurements of
LVEF [37, 38]. GLS has been shown to more accurately
predict cardiac events and all-cause mortality than LVEF
in the general population and in patients with heart fail-
ure [37, 39, 40]. It may also be useful in the prognosis of
individuals following myocardial infarction and cardiac
surgery and in those with cardiomyopathy, aortic sten-
osis and chronic kidney disease [37, 38].
Other measures of left ventricular morphology, and
particularly left ventricular mass and volume, may also
represent a common endpoint for other cardiovascular
risk factors including systolic blood pressure, body mass
index, smoking and diabetes [41]. In addition, increasing
left ventricular mass is associated with a greater risk of
sudden cardiac death in patients with stable CHD [42]
or uncomplicated essential hypertension [43, 44] and in
the general population [45].
Lipidomic profiling
Lipidomic analysis permits the simultaneous quantifica-
tion of several hundred lipid species within plasma,
thereby providing a global assessment of lipid metabolism
[46–48]. While Framingham cardiovascular risk assess-
ment and broader cardiovascular assessment incorporate
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a small number of lipid profile elements (notably triglycer-
ides, total cholesterol, HDL (high-density lipoprotein)-C
and LDL (low-density lipoprotein)-C) it has been argued
that these parameters only provide a very narrow snapshot
of the dynamic processes of lipid metabolism [46].
Compared to conventional clinical assessments, lipido-
mic approaches not only enable the quantification of a
far greater number of lipid classes and individual species
within plasma (up to approximately 600 lipid species),
but can also be applied to lipoprotein sub-fractions in-
cluding LDL, HDL and very low-density lipoprotein
(VLDL) giving greater mechanistic context. Given the
pivotal role that lipids play in the pathophysiology of
atherosclerotic CVD, new lipidomic technologies pro-
vide a way of identifying novel lipid species involved in
the pathogenesis of cardiovascular disease and which
have potential as biomarkers of future disease risk [46].
Using lipidomic profiling Meikle and colleagues under-
took a targeted lipidomic analysis of 305 lipid species in
plasma from 220 individuals who were either healthy,
had stable CHD or unstable CHD [47]. Results indicated
that individuals with atherosclerosis had altered lipid
metabolism and that specific lipid profiles could be cor-
related with different stages of CHD (healthy, stable
CHD, unstable CHD) [46, 47]. In more recent work, Mei-
kle and colleagues identified plasma lipid species that are
associated with future cardiovascular events and cardio-
vascular death in individuals with type 2 diabetes mellitus
and demonstrated that a subset of these can be used to
improve prediction of cardiovascular outcomes compared
to currently used prediction tools [49]. More generally,
Stegemann and colleagues demonstrated in a prospective
population study that three lipid species isolated and mea-
sured via lipidomics profiling improved cardiovascular risk
prediction over traditional risk factors [50]. Such studies
indicate that lipidomic profiles may have value for predic-
tion of CHD and CVD more generally. Furthermore, such
detailed understanding of the lipidome is particularly im-
portant given the emergence of newer therapies that target
pathways not modulated by existing pharmacotherapy in-
cluding HDL and PCSK9-targeted therapies [51–53].
Study aim and hypothesis
Given previous findings that traditional risk factors for
CVD derived from non-Indigenous Australian popula-
tion cohorts may only provide limited predictive power
in Indigenous Australian and other similarly disadvan-
taged [54, 55] populations, it is timely to re-examine sys-
tems for the assessment of CVD risk or detection of
pre-clinical CVD in greater detail in this setting. To do
this we plan to undertake a combined cross-sectional
and prospective study to investigate techniques for im-
proved CVD risk assessment and early CVD detection.
We will do this by using novel markers that may assist
in the identification of who is at greatest risk of subse-
quently developing overt CVD and in turn would benefit
from targeted primary and secondary preventive initia-
tives. In addition, we will seek to determine if such asso-
ciations are demonstrated in both Indigenous and non-
Indigenous Australians and, if restricted to Indigenous
Australians, whether they act differently in those resid-
ing in remote as compared with urban locations.
Accordingly, in undertaking the BIRCH study, we hy-
pothesise that markers of sleep quality/disorders, left
ventricular function/morphology and select lipidomic
species will:
1. explain more of the actual risk of the subsequent
development of overt CVD in Indigenous Australian
adults residing in remote Australia;
2. have equivalent additional explanatory power in
Indigenous Australians residing in urban locations; and
3. capture some, but less, of the currently unexplained
CVD risk in non-Indigenous Australians. (see Fig. 1)
It is anticipated the findings of this study and inclusion of
these novel risk factors will provide evidence to inform the
ongoing development of CVD risk detection, particularly in
Indigenous and other vulnerable populations, and provide
potential targets for the evaluation of interventions to en-
hance primary and secondary prevention of CVD.
Methods/design
Study design
BIRCH is a cross-sectional and prospective observational
cohort study of Aboriginal and Torres Strait Islander
(Indigenous) and non-Indigenous Australian adults (≥
18 years) living in remote and urban Australia. It will ad-
here to STROBE guidelines [56]. BIRCH will adopt a
three-phase approach that will reflect the hypotheses
outlined above (see Fig. 1), first focusing on Indigenous
Australians living in remote Australia, then urban-based
Indigenous Australians and finally non-Indigenous Aus-
tralians. Participants will be assessed for traditional CVD
risk factors as well as potentially novel risk factors com-
prising sleep quality/disorders, detailed lipid profiles and
markers of pre-clinical CVD including left ventricular
function and morphology. Outcome data will comprise
CVD events and CVD-related and all-cause mortality
over a period of five years.
Sample size
Sample size estimations will reflect the three-phase re-
cruitment outlined above and in Fig. 1 and assume a
two-side alpha of 0.05 and power of 80%. The first phase
will investigate the increased predictive power of the in-
clusion of novel markers for future CVD risk in Indigen-
ous Australians residing in remote Australia. It will
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assume an anticipated calculated Framingham-based
five-year absolute CVD risk of 2.6% in line with earlier
studies in this setting [13]. It is hypothesised that the
addition of these novel measures will increase by 5% the
correct identification of those who go on to develop
overt CVD such that the absolute explained risk will be
7.6% compared to the current identification of only 2.6%
utilising Framingham calculations. Based on these as-
sumptions 115 participants will be required to detect this
difference. This first phase in remote-residing Indigenous
Australians will be expanded to 500 to take account of a
potential failure to link all participants to administrative
data sets relating to mortality and hospital separation, the
exclusion of participants found to already have CVD at
the time of enrolment, and the need for greater numbers
to address subsequent hypotheses.
The second phase will investigate whether the additional
predictive benefit of these novel markers is equivalent in
remote and urban residing Indigenous Australians. It will
hypothesise the anticipated Framingham-based five-year
absolute risk of CVD of 2.6% is comparable in remote and
city-based Indigenous participants. It will assume any dif-
ference in study-determined absolute risk for development
of overt CVD (utilising novel measures) in the remote as
compared with urban Indigenous cohorts will be less than
3%. Based on equivalence testing this would then require
738 Indigenous Australian participants, 369 remote and
urban. Taking account of loss to follow-up and exclusion
of those with pre-existing CVD this will be increased to
1000 in total with 500 remote and 500 urban Indigenous
Australian participants.
The third and final phase of BIRCH will assume the
additional predictive power of novel risk and disease
markers will be less for non-Indigenous as compared
with Indigenous Australian participants. It will assume
the greater absolute risk of CVD explained by the
addition of novel markers will be 2% in non-Indigenous
Australian participants and, as for phase one, 5% for In-
digenous Australian participants. To detect this differ-
ence will require 1176 participants, 588 Indigenous and
588 non-Indigenous participants. Given 1000 Indigenous
Australian participants will be required for phase two of
the study it is proposed a similar number of non-
Indigenous Australian participants is recruited to ad-
dress the highlighted issues above.
In summary the BIRCH study will anticipate enrolling
a total of 2000 participants across three study phases in-
cluding 500 Indigenous Australians residing in remote
Australia, 500 Indigenous Australians residing in urban
Australia and 1000 non-Indigenous Australians.
Enrolling participants and informed consent
Potential participants will be recruited via a convenience
sampling method. Whilst this will be an opportunistic
community-based sample, we will aim to ensure that the
gender and age distribution of the cohort will reflect that
of the broader Indigenous and non-Indigenous Austra-
lian population [18].
Recruitment will take place with the assistance of local
key informants with input from local research assistants
and primary health care centres. In order to contact and
enroll potential participants, BIRCH staff may visit the
homes of such potential participants in the company of a
local health care staff member or, where appropriate, a
community-based Indigenous Australian research assistant.
Potential participants will be informed about the study
using local media, community groups, Indigenous re-
search staff and local language translators as required.
Fig. 1 BIRCH research hypotheses and associated sample size required
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Plain language patient information sheets will be pro-
vided and written informed consent obtained.
Ethics
Participant recruitment and data collection for BIRCH
will not commence at any site until approval has been
granted by the relevant local human ethics research
committees. The process of seeking ethics approval will
necessarily involve consultation with local community,
health and other stakeholders as well as consideration of
local cultural issues.
Data collection and outcomes
CVD risk assessment of participants will entail collection
of data outlined in the Box below.
• Demographic data
• Family history of cardiovascular disease (self-report)
• Co-morbidities and medication use (review of primary health care
medical records and hospital separation data for the last ten years,
current Pharmaceutical Benefits Scheme (Australian national medica-
tion subsidy scheme) dispensing history for urban-based participants)
• Lifestyle behaviours – smoking, alcohol (self-report)
• Clinical examination – blood pressure (Omron HEM-7130, Omron
Corp., Kyoto, Japan), weight, height, waist/hip/neck circumference
(standard anthropometric measurement methods)
• Investigations - blood chemistry comprising HbA1c, total
cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, non-HDL-
cholesterol, total cholesterol/HDL-cholesterol ratio. Blood chemistry
will be measured from aliquots of venous blood collected from par-
ticipants and analysed using an Alere Afinion™ AS100 Analyzer (Alere
Inc., Waltham, MA, USA)
At the time of initial assessment, participants will be
provided with general feedback regarding their CVD risk
profile based on existing Australian guidelines [57–61]
and information regarding potential lifestyle changes
that may reduce risk. If results of these initial
investigations reveal any previously undetected chronic
disease, then follow-up with local primary care centres
will be facilitated.
In addition to collecting and communicating data
regarding conventional clinical cardiovascular risk
factors, the following investigations will be undertaken:
 Echocardiography with specific reference to left
ventricular mass, function and strain studies (STE).
This will reflect the approach of earlier studies as
undertaken by Marwick and others [62]. Data will
be collected using a standard operating procedure
for image acquisition including two dimensional
imaging, colour Doppler and pulse and continuous
wave spectral Doppler analysis using a portable
echocardiography platform (Vivid Q, GE Medical
Systems, Milwaukee, WI, USA). Analysis of acquired
data will be undertaken by a single core laboratory
at Baker Heart and Diabetes Institute (Melbourne,
VIC, Australia) using standardised analysis and
reporting protocols.
 Screening home-based polysomnography (PSG) and/
or actigraphy [63] for assessment of sleep disordered
breathing (including obstructive sleep apnoea) and
sleep quality respectively. PSG will include multi-
channel recording including oximetry, ECG, EEG,
EMG, flow and chest and abdomen excursion using
a small portable recorder (Alice PDx, Philips
Respironics). A sleep scientist will attach equipment
in the late afternoon and retrieve it in the morning.
Polysomnography data will be analysed by a single
core laboratory at the Woolcock Institute of Medical
Research (The University of Sydney, NSW,
Australia) using standardised analysis and reporting
protocols. Actigraphy will involve participants
wearing a device (ActiGraph wGT3X-BT, ActiGraph,
Pensacola, FL, USA) attached to the waist for a
minimum of 3 days that monitors sleep/wake patterns
through recording of physical movement. Analysis
of actigraphy recordings will be undertaken according
to a standardised protocol by the same trained
researcher at the MacKillop Institute, Australian
Catholic University (Melbourne, Australia).
 Lipidomic analysis of both whole plasma and
lipoprotein sub-fractions will be undertaken at Baker
Heart and Diabetes Institute with an emphasis on
HDL composition using electrospray-ionisation
tandem mass spectrometry and HDL particle size
and distribution using nuclear magnetic resonance
(NMR) spectroscopy [47, 64].
If any of these specific investigations reveal a clinical
relevant abnormality then research staff will make
contact with participants and their local health care
provider to facilitate appropriate follow-up.
Once these data have been collected and analysed, any
participant found to have a pre-existing CVD based on
primary care or hospital separation data will be excluded
from further analysis and follow-up. The remaining par-
ticipants will be stratified according to exposure. Expos-
ure will be defined as the presence of conventional and
potentially novel cardiovascular risk factors. Outcome
data relating to CVD events and mortality over a five
year follow-up period will be collected:
 Cardiovascular event data will be collected based
on data linkage using ICD-10 [65] based hospital
separation coding for CVD. This will included a
diagnosis code range I20–I25 and procedure code
blocks 669–679, reflecting the methodology of
McDermott et al. [16].
 All cause and cardiovascular mortality will be
ascertained using jurisdictional data and the
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National Death Index maintained by the Australian
Institute of Health and Welfare.
Blinding
Researchers involved in collecting and analyzing
participant data under the four separate components of
the BIRCH project (conventional risk factor assessment,
echocardiography, PSG/actigraphy, lipidomics) will be
blinded as to the participant’s assessment in other
components of the study. Thus the researchers tasked
with collecting data on conventional risk factors, the
sonographers and cardiologist reporters involved in
measuring and reporting left function and morphology
via echocardiography, the technicians and sleep
specialists responsible for reporting portable PSG/
actigraphy, and the researchers tasked with undertaking
lipidomics analysis will be blinded to results obtained by
other researchers. Furthermore, the researchers involved
in collection of outcome data will be blinded as to each
participant’s baseline assessment.
Data management
All data collected on paper-based forms will be for-
warded to an independent data management unit at the
MacKillop Institute for processing in REDCap (Research
Electronic Data Capture) according to standard operat-
ing procedures. Reports from the echocardiogram, PSG,
actigraphy and lipidomics investigations will be received
in electronic format and integrated with the other per-
sonal and health related information. All electronic data
will be stored in a password-protected folder on a net-
work drive that is regularly archived.
Records will be de-identified and these non-
identifiable data will be analysed using STATA version
14 (StataCorp, College Station, Tex, USA). No identify-
ing information will be published or disseminated upon
completion of the study.
Data will be stored for five years following the
publication of research results or the end of study
whichever is the later as per recommended guidelines [66].
Statistical analysis
Data analysis will comprise descriptive statistics relating to
previously detected and undetected CVD, the presence of
traditional and potentially novel CVD risk factors, and
assessment of CVD risk [10]. The relationship between
traditional and potentially novel CVD risk factors will be
investigated by correlational analysis controlling for
relevant covariates. Subsequent data analysis will investigate
factors independently associated with CVD events and
mortality during a five year follow-up period. The influence
of traditional and putative novel (echocardiographic, lipido-
mic and sleep) CVD factors will be determined using sur-
vival analysis with the log-rank test (Freedman method)
and Cox proportional hazard modelling. As pre-existing
cut-offs for novel risk factors do not exist, receiver operator
characteristic analysis will be undertaken controlling for
traditional risk factors. Appropriate cut-offs will be identi-
fied with a focus on the highest sensitivity for the presence
or development of CVD. These cut-offs will be utilised in
subsequent Cox proportional hazard modelling and a risk
score developed using a derivation subset of the sample.
The utility of this score in predicting CVD will validated
using a subset of the sample and standard diagnostic valid-
ation techniques including sensitivity and specificity and
positive and negative predictive value.
Discussion
CVD risk assessment in disadvantaged populations,
including Indigenous Australians, remains an ongoing
challenge. Despite CVD being a major contributor to
overall health disadvantage in Indigenous Australians,
there exist significant deficiencies in currently used CVD
prediction tools. This hinders the ability of health
services to target and deliver primary prevention
initiatives to those individuals at greatest need.
Furthermore, the presence of increased CVD burden
unexplained by traditional risk factor prediction also
challenges the existing understanding regarding the
mechanisms responsible for CVD development in this
unique Indigenous Australian population.
In the context of this background, BIRCH aims to
enhance the understanding of factors responsible for the
greater burden of CVD disease in Indigenous Australians.
While many existing and newer markers of early CVD
disease or risk may help identify Indigenous Australians at
increased risk of development of overt CVD, the BIRCH
project specifically focuses on three markers comprising:
sleep quality and disorders, left ventricular function and
morphology, and select lipidomic species. These
markers were chosen as they are potential targets for
primary and/or secondary prevention in this setting. If
results of the BIRCH study do indeed indicate that
these markers are able to explain more of the actual
risk of the subsequent development of overt CVD in
Indigenous Australian adults then interventions are
available that can be employed sooner to prevent or
delay the onset of disease.
In turn, BIRCH will potentially provide information to
inform the development of more accurate tools for CVD
risk prediction as a means for improving the targeting of
existing and emerging preventive therapies in those at
greatest risk of heart disease, ensuring those who can
gain the greatest benefit are identified and treated early.
Finally, the BIRCH cohort will form a valuable future
and ongoing resource to facilitate early evaluation of
new treatments to prevent and manage CVD. Together
these elements will serve to support the development of
Rémond et al. BMC Cardiovascular Disorders  (2017) 17:228 Page 7 of 9
effective, appropriate and sustainable interventions to
prevent progression and complications of CVD in
Indigenous Australians, thereby addressing this significant
contributor to health disparity.
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